SANOFI.NSE Sanofi India Ltd

 Sanofi India Q4: Revenue came in at Rs 732.4 crore, down 0.5 percent from the year-ago quarter

Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category

The share touched a 52-week high of Rs 9,370.35 and a 52-week low of Rs 5,329.70 on 23 February, 2024 and 03 May, 2023, respectively.